SCHEMBL24345265

SCHEMBL24345265

CC1(N)COc2c1cc(Cl)nc2-c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 9/20 0.43
ADORA1 P30542 8/20 0.43
ADORA2B P29275 3/20 0.43
ADORA3 P0DMS8 1/20 0.43
THRB P10828 1/20 0.32
KIT P10721 1/20 0.32
AKT1 P31749 1/20 0.32
AKT2 P31751 1/20 0.32
MAPT P10636 1/20 0.31
PKM P14618 1/20 0.31
NPC1 O15118 1/20 0.31
TP53 P04637 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31
MAPK13 O15264 1/20 0.31
GCGR P47871 1/20 0.31
MAPK12 P53778 1/20 0.31
MAPK11 Q15759 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24345285 1.00 ADORA2A (0.43) ADORA2AADORA1ADORA2BADORA3THRB
SCHEMBL23905618 0.81 ADORA2A (0.36) ADORA2AADORA1ADORA2BADORA3MAPT
SCHEMBL23905585 0.80 ADORA2A (0.36) ADORA2AADORA1ADORA2BADORA3
SCHEMBL23904879 0.79 ADORA2A (0.35) ADORA2AADORA1ADORA2BADORA3THRB
SCHEMBL23904778 0.78 ADORA2A (0.36) ADORA2AADORA1ADORA2BADORA3MAPK14
SCHEMBL31412373 0.77 BACE1 (0.34) ADORA2AADORA1ADORA2BMAPK13MAPK12
SCHEMBL23904878 0.77 ADORA2A (0.35) ADORA2AADORA1ADORA2BADORA3MAPK14
SCHEMBL23905717 0.76 ADORA2A (0.33) ADORA2AADORA1ADORA2BADORA3
SCHEMBL23904761 0.76 ADORA2A (0.33) ADORA2AADORA1ADORA2BADORA3
SCHEMBL29620708 0.76 ADORA3 (0.32) ADORA2AADORA1ADORA2BADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022086840-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2022-04-28 WO disclosed
US-20220119398-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119398-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS VIP, ACE, FURIN ADORA2A 1689/4885ADORA1 1695/4885ADORA2B 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.